AEON Biopharma (NYSE American: AEON) announced that its management team will host in-person 1x1 investor meetings at Lake Street Capital Markets’ 10th Annual Best Ideas Growth (BIG10) Conference in New York City on Thursday, September 10, 2026. Interested investors should contact their Lake Street representative for invitations and scheduling.
Loading...
Loading translation...
Positive
None.
Negative
None.
Market Context
Timothy P. Lynch's Form 4 recorded a purchase of 1,150,000 shares, providing ownership context for A...
Analysis
Timothy P. Lynch's Form 4 recorded a purchase of 1,150,000 shares, providing ownership context for AEON's investor-meeting announcement. The active S-3 resale registration and ongoing financing needs remained relevant risks to monitor.
Upsized offering priced with milestone warrants and potential future funding
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
Recent AEON news showed mixed reactions, with three aligned responses and two divergences between announcement sentiment and subsequent price reaction.
Key Terms
biosimilar, onabotulinumtoxina
2 terms
biosimilarmedical
"advancing ABP-450 as a biosimilar to BOTOX"
A biosimilar is a medicine created to be highly similar to an existing complex drug made from living cells, matching its safety and effectiveness while allowing for small, natural variations. For investors, biosimilars matter because they introduce lower-cost competition when patents end, which can cut prices, shift market share, and change revenue forecasts for companies selling the original drugs, much like a generic version does for simpler chemical medicines.
onabotulinumtoxinamedical
"BOTOX® (onabotulinumtoxinA) for therapeutic use"
Onabotulinumtoxina is a prescription form of botulinum toxin type A, a purified protein given by injection in very small doses to temporarily relax muscles and block certain nerve signals; it is used for cosmetic purposes like reducing wrinkles and for medical conditions such as chronic migraine, muscle spasms, and excessive sweating. Investors track its sales, regulatory approvals, patent life, and safety profile because changes to demand, labeling, or competition for this single product can significantly affect a drugmaker’s revenue and growth—similar to how a popular flagship product can drive an electronics company’s fortunes.
ALISO VIEJO, Calif., Aug. 31, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 as a biosimilar to BOTOX® (onabotulinumtoxinA) for therapeutic use to achieve full-label U.S. market entry, announced today that AEON management will host in-person 1x1 investor meetings at Lake Street Capital Markets’ 10th Annual Best Ideas Growth (BIG10) Conference being held in New York City on Thursday, September 10th, 2026.
To receive additional information about the Conference, request an invitation or to schedule a one-on-one meeting, please contact your Lake Street Representative.
About AEON Biopharma
AEON Biopharma is a biopharmaceutical company pursuing full-label access to the U.S. therapeutic neurotoxin market via biosimilarity to BOTOX®. The U.S. therapeutic neurotoxin market exceeds $3.0 billion annually, representing a major opportunity for biosimilar entry. ABP-450 is the same botulinum toxin complex currently approved and marketed for cosmetic indications by Evolus, Inc. under the name Jeuveau®. ABP-450 is manufactured by Daewoong Pharmaceutical in a facility that has been authorized by the U.S. Food and Drug Administration, Health Canada, and European Medicines Agency for the manufacture of third-party botulinum toxin products. AEON has exclusive development and distribution rights for therapeutic indications of ABP-450 in the United States, Canada, the European Union, the United Kingdom, and certain other international territories. To learn more about AEON, visit www.aeonbiopharma.com.
What is AEON Biopharma (AEON) announcing on August 31, 2026?
AEON Biopharma announced it will host in-person 1x1 investor meetings at the Lake Street BIG10 Conference. According to AEON Biopharma, these meetings will occur in New York City on September 10, 2026, and are arranged via Lake Street representatives.
When and where will AEON Biopharma (AEON) attend the Lake Street BIG10 Conference in 2026?
AEON Biopharma will participate in Lake Street’s 10th Annual Best Ideas Growth (BIG10) Conference on September 10, 2026. According to AEON Biopharma, the event will be held in New York City and will include in-person one-on-one investor meetings.
How can investors schedule 1x1 meetings with AEON Biopharma (AEON) at the BIG10 Conference?
Investors can schedule one-on-one meetings with AEON Biopharma by contacting their Lake Street representative. According to AEON Biopharma, the representative can provide additional conference information, handle invitation requests, and arrange individual investor meetings for the September 10, 2026 event.
What type of company is AEON Biopharma (NYSE American: AEON)?
AEON Biopharma is a biopharmaceutical company advancing ABP-450 as a biosimilar to BOTOX for therapeutic use. According to AEON Biopharma, its goal is to achieve full-label U.S. market entry with ABP-450, targeting medical indications rather than cosmetic applications.
What is ABP-450, the product being developed by AEON Biopharma (AEON)?
ABP-450 is a botulinum toxin product AEON Biopharma is advancing as a biosimilar to BOTOX for therapeutic use. According to AEON Biopharma, ABP-450 is intended to support full-label U.S. market entry across approved medical indications when developed successfully.
